InvestmentJun 24, 2026, 05:07 PM
CalciMedica Secures Up to $49M Private Placement; FDA Clears Auxora Trial
AI Summary
CalciMedica, Inc. announced a private placement financing for up to approximately $49 million in gross proceeds, with an upfront amount of $15 million. The financing involves the sale of 18,673,429 units to new and existing investors, including management and board members. The company intends to use the proceeds to advance its pulmonary hypertension program, including a Phase 1b study for Auxora and IND clearance for CM5480. Additionally, the FDA has reviewed interim safety data for CalciMedica's Phase 2 KOURAGE trial for Auxora and provided no comments, allowing clinical development to continue.
Key Highlights
- Secured private placement financing for up to approximately $49 million in gross proceeds.
- Upfront gross proceeds from the private placement are approximately $15.0 million.
- Issued an aggregate of 18,673,429 units, each comprising common stock/pre-funded warrant and Series A/B warrants.
- Proceeds will advance a focused pulmonary hypertension strategy, including Auxora Phase 1b and CM5480 IND.
- FDA reviewed protocol amendment and interim safety data for Auxora's KOURAGE trial with no comments.
- Clinical development of Auxora may proceed across indications following FDA review.
- Anticipated cash runway into 2H 2027 with the upfront proceeds.
Price Impact
More from CALC